非活性位点靶向纳米抗体库选择性调节活化蛋白C活性
研究利用美洲驼抗体构建靶向活化蛋白C(APC)非活性位点的纳米抗体库,鉴定出21个选择性识别APC而非蛋白C酶原的纳米抗体,分为3个竞争簇;功能试验揭示13种新型APC活性调节谱,其中LP11可改变PAR1切割位点比例并产生偏向性信号,可能促进止血和细胞保护。
要点
- 21个纳米抗体选择性识别APC而非蛋白C酶原,基于竞争分为3簇。
- 功能试验揭示13种纳米抗体诱导的APC活性调节谱。
- LP11改变PAR1 R46相对R41切割比例,产生偏向性PAR1信号。
核心结论
- 纳米抗体库可选择性调节APC的抗凝、组蛋白H3切割和PAR1切割活性,LP11的活性谱可能促进血友病或凝血病相关出血中的止血和细胞保护。
研究设计与样本
- 使用美洲驼抗体构建靶向APC非活性位点的纳米抗体库,鉴定21个选择性识别APC的纳米抗体,通过生物层干涉术竞争实验分为3簇,并用抗凝、组蛋白H3切割和PAR1切割功能试验分析。
主要发现
- 鉴定出21个选择性识别APC而非蛋白C酶原的纳米抗体,基于生物层干涉术竞争分为3簇。
- 功能试验揭示13种纳米抗体诱导的APC活性调节谱。
- LP2、LP8和LP17抑制全部3种APC功能;LP1、LP5、LP16和LP20仅抑制3种功能中的2种。
- 仅LP9和LP11单功能抑制APC抗凝活性;LP11改变PAR1 R46相对R41的切割比例,导致偏向性PAR1信号和APC细胞保护效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activated protein C (APC) is a pleiotropic coagulation protease with anticoagulant, anti-inflammatory, and cytoprotective activities. Selective modulation of these APC activities contributes to our understanding of the regulation of these physiological mechanisms and permits the development of therapeutics for the pathologies associated with these pathways. An antibody library targeting the nonactive site of APC was generated using llama antibodies (nanobodies). Twenty-one nanobodies were identified that selectively recognize APC compared with the protein C zymogen. Overall, 3 clusters of nanobodies were identified based on the competition for APC in biolayer interferometry studies. APC functional assays for anticoagulant activity, histone H3 cleavage, and protease-activated receptor 1 (PAR1) cleavage were used to understand their diversity. These functional assays revealed 13 novel nanobody-induced APC activity profiles via the selective modulation of APC pleiotropic activities, with the potential to regulate specific mechanisms for therapeutic purposes. Within these, 3 nanobodies (LP2, LP8, and LP17) inhibited all 3 APC functions. Four nanobodies (LP1, LP5, LP16, and LP20) inhibited only 2 of the 3 functions. Monofunction inhibition specific to APC anticoagulation activity was observed only by 2 nanobodies (LP9 and LP11). LP11 was also found to shift the ratio of APC cleavage of PAR1 at R46 relative to R41, which results in APC-mediated biased PAR1 signaling and APC cytoprotective effects. Thus, LP11 has an activity profile that could potentially promote hemostasis and cytoprotection in bleedings associated with hemophilia or coagulopathy by selectively modulating APC anticoagulation and PAR1 cleavage profile.
引用
- Sim DS, Shukla M, Mallari CR, et al. Selective modulation of activated protein C activities by a nonactive site-targeting nanobody library. Blood Adv. 2023. PMID: 36735416. doi:10.1182/bloodadvances.2022008740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。